~~<i id='6B2BC6EDBC'><strike id='6B2BC6EDBC'><tt id='6B2BC6EDBC'><pre id='6B2BC6EDBC'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：explore 2025-10-01 20:18:14 Page View：16573

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Congress: Prevent baby formula shortages by passing a new bill
Next article： Alkermes shareholders re

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Test for long Covid? Researchers find new clue in blood samples

AdobeLongCovidhaslongeludedscientistslookingforitscause.Notknowingwhattriggersitspersistentanddistre

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Should insurance cover cosmetic surgery?

ATTAKENARE/AFP/GettyImagesShouldinsurancecoverbreastaugmentation,theprocedurecommonlyknownasaboobjob